Pyro70 wrote:FYI, I’m reposting from the MSS Facebook group. There are also two trials one can join to test this combo. Pembrolizumab should be equivalent to nivolumab and there is a trial in Southern California and Florida. There is also a trial recruiting in Florida for reg + Opdivo.
NCT03712943 (rego + nivolumab (Brand name Opdivo; anti PD-1))
NCT03657641 (rego + pembrolizumab (Brand name Keytruda (anti PD-1))
Interesting there is also this trial below that is completed, that I would love to see the results for:
NCT03081494 (rego + spartalizumab/PDR001 (experimental anti PD-1 by Novartis))
It’s great to hear of these clinical trials — I hope they yield promising results.
Our onc informed us that in one clinical trial involving regorafenib + nivolumab, the patients are randomly placed into one of two groups: 1) an investigational group that receives both regorafenib + nivolumab and 2) a control group that receives only regorafenib. I do not know if it is the same clinical trial as the one referenced above. In any case, please keep this in mind for anyone considering enrolling in a trial. It is possible for you to be placed in a control group and not even receive the meds you wanted to try.